|
| Thursday, December 15, 2022 |
|
|
Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases |
| Eisai Co., Ltd. announced today that Eisai and Washington University School of Medicine in St. Louis have entered into a comprehensive research collaboration agreement aiming to create potential novel treatments for neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). more info >> |
|
| Thursday, December 1, 2022 |
|
|
Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium |
| Eisai Co., Ltd. announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN, "eribulin") will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10. more info >> |
|
| Wednesday, November 30, 2022 |
|
|
Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease at Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai Co., Ltd. and Biogen Inc. announced today that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab. more info >> |
|
|
Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer's Disease in the New England Journal of Medicine |
| The rapid publication of the Clarity AD study results demonstrates Eisai's strong commitment to trust and transparency based on Eisai's human health care mission. more info >> |
|
| Tuesday, November 29, 2022 |
|
|
Eisai Announces Approval of Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies |
| Eisai Co., Ltd. announced that its application for a partial change to label for Aricept (donepezil hydrochloride), a treatment for Alzheimer's disease and dementia with Lewy bodies (DLB) that was discovered and developed in-house, regarding dosage and administration for the treatment of DLB in Japan, has been approved today. more info >> |
|
| Thursday, November 24, 2022 |
|
|
Eisai to Present Latest Data on Perampanel at the 76th American Epilepsy Society (AES) Annual Meeting |
| Eisai Co., Ltd. announced today that the company will have a total of 34 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel at the 76th American Epilepsy Society Annual Meeting (AES 2022), to be held in Nashville, Tennessee and virtually from December 2-6, 2022. more info >> |
|
| Tuesday, November 22, 2022 |
|
|
To Develop Japan's First Blood Biomarker-Based Diagnostic Workflow for Dementia Shimadzu, Eisai, Oita University, and Usuki City Medical Association Commence Joint Research |
| Shimadzu Corporation (Shimadzu), Eisai Co., Ltd. (Eisai), Oita University, and Usuki City Medical Association hereby announce the commencement of a cohort study using Usuki City as a demonstration site. more info >> |
|
| Monday, November 21, 2022 |
|
|
Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer's Disease Research at The 15th Clinical Trials on Alzheimer's Disease (CTAD) Conference |
| Eisai's AD pipeline, including the company's investigational anti-microtubule binding region (MTBR) tau antibody (E2814), will be presented in four oral and ten poster presentations. more info >> |
|
| Wednesday, November 16, 2022 |
|
|
Metoject Subcutaneous Injection Syringe (Methotrexate) Launched In Japan For Rheumatoid Arthritis |
| Eisai Co., Ltd. and nippon medac Co., Ltd. announced today that they have launched the anti-rheumatic agent "Metoject Subcutaneous Injection 7.5mg syringe 0.15mL, 10mg syringe 0.20mL, 12.5mg syringe 0.25mL and 15mg syringe 0.30mL" (methotrexate, "MTX") in Japan. more info >> |
|
| Monday, November 7, 2022 |
|
|
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH |
| Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myonal (generic name: eperisone hydrochloride) and vertigo and equilibrium disturbance treatment Merislon in Asia (9 countries/regions*) to a subsidiary of DKSH Holding Ltd more info >> |
|
|
|
